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ABSTRACT
Introduction: Heart failure (HF) patients are at risk for venous thromboembolism (VTE) during
the hospital stay. We aim to study the recent trend of deep vein thrombosis (DVT), pulmonary
embolism (PE), and VTE in heart failure patients from years 2000–2013.
Methods: We utilized the National (Nationwide) Inpatient Sample database and selected non-
pregnant patients over the age of 18 years for this purpose. We selected HF, DVT, PE, and VTE
based on International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-
9-CM). We used STATA for analysis.
Results: We noted an increase in prevalence of DVT, PE and composite VTE among HF
hospitalizations from 0.55%, 0.17% and 0.76% in 2000 to 0.96%, 0.4% and 1.46%, respectively,
in 2013 and a decrease in trend of mortality among HF hospitalizations associated with DVT,
PE and VTE from 8.95%, 16.36% and 10.80% in 2000 to 6.78%, 7.92% and 7.20%, respectively,
in 2013.
Conclusion: Increasing prevalence of VTE is concerning and suggests that we still need to
work on delivering prophylaxis to all HF inpatients.
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Hospitalized heart failure (HF) patients are at risk for
development of venous thromboembolism (VTE) [1].
The American College of Chest Physicians Consensus
Conference on Antithrombotic Therapy recommends
VTE prophylaxis in all inpatients diagnosed with HF
[2,3]. However, previous studies have shown low
rates of VTE prophylaxis use in this population [4].
Imaging modalities for VTE have greatly expanded in
use in the past two decades, increasing detection rates
with a reported decrease in overall mortality [5].
Faced with these competing trends, we sought to
study DVT/PE incidence among hospitalized HF
patients in a nationwide database.
2. Methods
2.1. Study population
We utilized the National (Nationwide) Inpatient
Sample database from years 2000–2013. We selected
non-pregnant patients over the age of 18 admitted
with HF in US hospitals over the specified period. We
chose records with HF in the primary diagnosis posi-
tion to increase the specificity of the hospitalization
being due to HF. We selected patients with DVT or
PE based on International Classification of Diseases,
Ninth Revision, Clinical Modification (ICD-9-CM)
and Clinical Classification Software-Diagnoses codes
supplied by the Healthcare Cost and Utilization
Project (HCUP). We created a composite of all
patients with diagnosis of DVT, PE or both diag-
noses, which we called ‘VTE’ in our analysis.
2.2. Statistical analysis
We used STATA version 13.0 (College Station, TX)
for database analysis and Joinpoint Regression
Program version 4.5.0.1 to plot yearly trends of pre-
valence and mortality with DVT, PE or VTE among
hospitalized HF patients. Descriptive data were
expressed as percentages and the change in yearly
trend was expressed as an annual percentage change
(APC) with a significance level of p < 0.05.
3. Results
We identified a total of 3,154,121 patients coded with HF
in primary diagnosis position from 2000 to 2013. Among
them, 36,445 (1.2%) had an associated diagnosis of VTE
(DVT: n = 25,624; PE: n = 8,505; both DVT and PE: n =
2,316). The prevalence of DVT, PE and composite VTE
among HF hospitalizations increased from 0.55%, 0.17%
and 0.76% in 2000 to 0.96%, 0.4% and 1.46%, respec-
tively, in 2013 (Figure 1). The yearly trend of mortality
amongHF hospitalizations associated with DVT, PE and
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VTE decreased from 8.95%, 16.36% and 10.80% in 2000
to 6.78%, 7.92% and 7.20%, respectively, in 2013 (Figure
2). Inpatient mortality was higher in patients with heart
failure as compared to all other admissions, but higher
still for patients with HF was associated with DVT or PE
throughout the time studied (Figure 2). Trend analysis
for all HF hospitalizations showed that total hospitaliza-
tions decreased over the time of the study (APC: −1.59,
Figure 1. Yearly trend of overall hospitalizations, HF hospitalizations, and prevalence/proportion of HF with DVT, PE, and VTE –
results from Joinpoint Regression Analyses.
* APC = Annual Percentage Change, DVT = Deep vein thrombosis; HF = Heart Failure; PE = Pulmonary embolism; VTE = Venous thromboembolism.
Figure 2. Yearly trend of mortality among overall hospitalizations, HF hospitalizations, HF with DVT, PE, and VTE – results from
Joinpoint Regression Analyses.
* APC = Annual Percentage Change, DVT = Deep vein thrombosis; HF = Heart Failure; PE = Pulmonary embolism; VTE = Venous thromboembolism.
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p-value<0.05), but the proportions of DVT, PE and VTE
among HF hospitalizations increased over this time
(APCs 2.70, 6.55 and 4.23, respectively, p < 0.05 for all)
(Figure 1). In contrast, we found an overall decreasing
trend inmortality among all HF hospitalizations (with or
without VTE) (APC: −1.77; p-value<0.05) and among
HF hospitalizations associated with any VTE
(APC = −3.21; p-value<0.05), PE (APC = −5.73;
p-value<0.05) or DVT (APC = −2.19; p-value<0.05).
Mortality among HF patients with heart failure and
concomitant PE had the largest decrease of any of the
trends studied. The mortality among hospitalizations of
all diagnoses also had a decreasing trend over the same
period (APC: −3.34; p-value<0.05) (Figure 2).
4. Discussion
In a large US inpatient database sample over 14 years,
we identified an increasing prevalence of DVT, PE or
VTE among HF hospitalizations but a decreasing rate
of inpatient mortality among all groups. Our findings
mirror those of a prior study by Huang et al. [6] in
which the incidence rate of VTE among an unse-
lected population was found to have increased over
the past 30 years. However, a separate study by
Beemath et al. [1] on a population of HF inpatients
identified increased incidence of DVT but decreasing
rates of PE between 1979 and 2003, while a second
study by the same author identified a decreasing rate
of PE mortality in HF inpatients (5% in 1980 to 1.6%
in 1998) [7]. We found a similar reduction in mor-
tality among HF hospitalizations not only with PE
but also with DVT and overall VTE. These decreasing
mortality rates could be due to improvement in man-
agement of inpatient VTE but also could be due to
increasing utilization of highly sensitive imaging
modalities leading to over-detection of non-fatal
DVTs and smaller burden PEs [3]. However, given
the reduction in mortality among overall hospitaliza-
tions, this raises a question as to whether the noted
decrease in mortality with DVT, PE or VTE among
HF hospitalizations is simply reflective of overall
improved inpatient survival.
4.1. Strengths and limitations
The NIS database is the largest all-payer database
representing the largest number of hospitalizations
in the US. Thus, it is a more real-world representa-
tion of the inpatient care. However, the database is
comprised of discharge-level information which may
be subject to coding errors. Our study is also limited
by the inability to separate VTE that may have devel-
oped during prior hospitalization because the
diagnosis can be carried into the current admission
as patient may still be receiving treatment.
5. Conclusion
Patients with HF and VTE have a higher inpatient
mortality than those without VTE, and rates of HF
patients with VTE appear to be increasing. This raises
an important concern whether current systems for
delivering VTE prophylaxis are adequate in HF popu-
lations or whether better delivery of that prophylaxis
could affect rates of VTE in this population.
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